ILS-920，≥98% (HPLC)

Synonym: (3S,6R,7E,9R,10R,12R,14S,15S,18R,19E,21S,23S,26R,27R,34aS)-3,4,9,10,13,14,15,16,18,21,22,23,24,25,26,27,32,33,34,34a-eicosahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-16-phenyl-23,27-epoxy-15,18-ethenopyrido[2,1-r][1,16,2,19]dioxadiazacyclohentriacontine-1,5,11,28,29(6H,12H,31H)-pentone.

 

ILS-920 is a rapamycin derivative with reduced immunosuppressive activity and enhanced neuroprotective activities including efficacy in vivo stroke model. ILS-920 predominantly binds to FKBP52 with a 972-fold higher selectivity for FKBP52 vs. FKBP12 than that of rapamycin, and also binds to the β-subunit of L-type voltage dependent Ca²⁺ channels. This dual functionality may contribute to the compound′s efficacy in stroke models.

 

This compound was developed by Pfizer for Immunology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

 

Sold for research purposes under agreement from Pfizer Inc.

Pfizer is a registered trademark of Pfizer, Inc.